Literature DB >> 23545579

Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family.

Weiwei Feng1, Anais Malpica, Stanley J Robboy, Einar Gudlaugsson, Keqin Hua, Xianrong Zhou, Jan P A Baak.   

Abstract

The World Health Organization (WHO 2003) recognizes 3 endometrial stromal neoplasms: noninvasive endometrial stromal nodule and the 2 invasive neoplasms, endometrial stromal sarcoma (ESS), low grade and undifferentiated endometrial sarcoma (UES). It is important to note that the WHO 2003 does not define moderate atypia (an important differentiating diagnostic criterion for ESS, low grade and UES), nor does it discuss its significance. Moreover, studies on reproducibility and additional prognostic value of other diagnostic features in large are lacking. Using strict definitions, we analyzed the agreement between routine and expert-review necrosis and nuclear atypia in 91 invasive endometrial stromal neoplasias (IESN). The overall 5-year and 10-year recurrence-free survival rate estimates of the 91 IESN patients were 82% and 75%, respectively. Necrosis was well reproducible, and nuclear atypia was reasonably well reproducible. The 10-year recurrence-free survival rates for necrosis absent/inconspicuous versus prominent were 89% and 45% (P<0.001) and those for review-confirmed none/mild, moderate, severe atypia were 90%, 30%, and <20% (P<0.00001). Therefore, cases with moderate/severe atypia should be grouped together. Nuclear atypia and necrosis had independent prognostic values (Cox regression). Once these features were taken into account, no other feature had an independent additional prognostic value, including mitotic count. Using "none/mild atypia, necrosis absent/inconspicuous" as ESS, low grade versus "moderate/severe atypia present or necrosis present" as UES resulted in 68 ESS, low grade and 23 UES cases with disease-specific overall mortality-free survival of 99% versus 48% (P<0.00001, hazard ratio=45.4). When strictly defined microscopic criteria are used, the WHO 2003 diagnoses of ESS, low grade and UES are well reproducible and prognostically strong.

Entities:  

Mesh:

Year:  2013        PMID: 23545579     DOI: 10.1097/PGP.0b013e318229adfb

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

1.  High-grade endometrial stromal sarcoma versus undifferentiated uterine sarcoma: a Turkish uterine sarcoma group study-001.

Authors:  Ali Ayhan; Mehmet Tunc; Nurettin Boran; Ghanim Khatib; Mehmet Gokcu; Tayup Simsek; Ozlem Isiksacan Ozen; Tayfun Toptas; Ibrahim Yalcin; Mehmet Mutlu Meydanli
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

2.  Ewing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy.

Authors:  Anastasios Kyriazoglou; Georgios Tsironis; Michalis Liontos; Alexandra Papakosta; Luisa Mahaira; Nikolaos Thomakos; Georgios Morphopoulos; Irene Papaspyrou; Aristotelis Bamias
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

3.  Clinicopathological characteristics and treatment of patients with high-grade endometrial stromal sarcoma: A retrospective study of 40 cases.

Authors:  Huimin Bai; Fang Yuan; Bing Liang; Hengzi Sun; Yutao Gao; Mulan Jin; Xiaoming Xing
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

4.  Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Authors:  Weiwei Feng; Anais Malpica; Ivar Skaland; Einar Gudlaugsson; Stanley J Robboy; Ingvild Dalen; Keqin Hua; Xianrong Zhou; Jan P A Baak
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

5.  The value of clinical parameters combined with magnetic resonance imaging (MRI) features for preoperatively distinguishing different subtypes of uterine sarcomas: An observational study (STROBE compliant).

Authors:  Qiu Bi; Kunhua Wu; Fajin Lv; Zhibo Xiao; Yulin Xiong; Yiqing Shen
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.